)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Curis
Curis (CRIS) investor relations material
Curis Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Emavusertib plus BTKi showed PCNSL ORRs of 86% in BTKi-naive patients and 26% in BTKi-experienced patients; evaluable-patient rates were 100% and 33%, respectively.
TakeAim CLL and registrational TakeAim Lymphoma studies are enrolling; initial CLL data are expected in December 2026.
Financial highlights
Q3 2026 net loss was $8.1M, or $1.94/share, vs. $7.7M, or $9.86/share, in Q3 2025; 9M net loss was $40.9M, or $16.77/share, vs. $26.9M, or $43.82/share.
Revenue was $0 in Q3 and 9M 2026 following the Q4 2025 Erivedge royalty sale; comparable 2025 revenue was $3.2M and $8.3M.
Q3 R&D expense was $5.6M vs. $6.4M; 9M R&D was $18.8M vs. $22.4M, primarily reflecting lower employee costs, partly offset by higher clinical costs.
Q3 G&A expense was $3.2M vs. $3.7M; 9M G&A was $11.4M vs. $11.2M, with lower employee costs partly offset by higher legal costs.
Q3 other income was $0.6M vs. $0.8M other expense in Q3 2025; 9M other expense was $10.7M vs. $1.6M.
Outlook and guidance
PCNSL registrational-study enrollment is expected to complete by end-2027; management expects ~6 months of follow-up after last-patient enrollment and an accelerated-approval NDA filing in 2028, subject to enrollment timing.
Initial TakeAim CLL data are expected in December 2026 and may include available safety and clinical-activity data from patients with varying follow-up.
Existing cash plus October private-placement proceeds was expected to fund operations into Q1 2027; risk disclosure says resources are insufficient for the next 12 months.
FDA and EMA guidance indicated the ongoing registrational PCNSL study could support accelerated-approval applications.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Curis
- A proposed 1-for-5 to 1-for-12 reverse split aims to support Nasdaq compliance.CRIS
Proxy filing - Proposed reverse split targets Nasdaq compliance, but leaves execution to the board.CRISProxy filing
- Net loss increased, cash runway is short, and additional funding is urgently needed to sustain operations.CRISQ2 2026
- Best-efforts offering seeks up to $13.6M for R&D, but going concern risk and dilution remain high.CRISRegistration filing
- Emavusertib delivers superior efficacy and safety in hematologic cancers, advancing toward approval.CRISCorporate presentation
- Emavusertib plus BTKi achieves strong PCNSL responses and advances, pending further funding.CRISStudy update
- Q3 net loss narrowed, emavusertib data positive, but funding needed beyond mid-2025.CRISQ3 2024
- Emavusertib gains EU ODD as Q2 net loss hits $11.8M and cash runway extends into Q1 2025.CRISQ2 2024
- Emavusertib advances on accelerated approval path with strong data, improved financials, and funding risks.CRISQ4 2024
Next Curis earnings date
EGM 202618 Nov, 2026
Curis
Next Curis earnings date
EGM 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Curis Inc. is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company's research and development efforts concentrate on targeting signaling pathways that play a key role in the growth and survival of cancer cells. Curis works on both proprietary drug candidates and in collaboration with strategic partners to advance its oncology-focused pipeline. Its therapeutic approach includes small molecules and immunotherapies aimed at addressing various forms of cancer, with the goal of improving patient outcomes. The company is headquartered in Lexington, Massachusetts, and its shares are listed on the NASDAQ.